NTX-253
Asset
Allosteric modulator for schizophrenia
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Schizophrenia
Phase 1, globenewswire.com, 8 Oct 2026
In the full profile
- Owner and partners2
- Competitors6
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.